Drug Trial Radar · NCT05746611
Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,500
Actual
Start
Apr 17, 2023
Primary completion
May 13, 2024
Study completion May 13, 2024
Sponsor
- Lead sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Cohort 1 was a randomized, double-blind, controlled clinical trial with a planned enrollment of 500 patients. Cohort 2 is a non-randomized, open-label clinical trial with a planned enrollment of approximately 60000 patients. Cohort I was injected with EC and TB-PPD in both arms, and cohort II was injected with EC only
Conditions
- Latent Tuberculosis Infection
Interventions
Recombinant Mycobacterium tuberculosis fusion protein for injectionBiological
For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method
TB-PPD was injectedBiological
For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
Primary outcomes
What the sponsor says the trial is designed to measure.
- In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 0 minute after injection.
- In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 24 hours after injection.
- In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 48 hours after injection.
- In Cohort 1, the diameter of redness or induration at the reaction siteTime frame: The skin test was performed at 72 hours after injection.
- In Cohort 2, the diameter of redness or induration at the reaction siteTime frame: 0 minute after the skin test
- In Cohort 2, the diameter of redness or induration at the reaction siteTime frame: Within 48 to 72 hours after skin testing
- Number of cases in which all adverse events occurred.Time frame: The skin test was performed 72 hours after injection.
- Incidence of SAETime frame: Incidence of SAE within 72 hours after full vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
Liuzhou, Guangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.